Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
DNTH 
Dianthus Therapeutics Inc. (DNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: DNTH (1-star) is a SELL. SELL since 3 days. Simulated Profits (-6.76%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.63
1 Year Target Price $63.63
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77.74% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.63B USD | Price to earnings Ratio - | 1Y Target Price 63.63 |
Price to earnings Ratio - | 1Y Target Price 63.63 | ||
Volume (30-day avg) 12 | Beta 1.26 | 52 Weeks Range 13.37 - 45.45 | Updated Date 01/9/2026 |
52 Weeks Range 13.37 - 45.45 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -10173.74% |
Management Effectiveness
Return on Assets (TTM) -18.82% | Return on Equity (TTM) -28.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1233105691 | Price to Sales(TTM) 531.01 |
Enterprise Value 1233105691 | Price to Sales(TTM) 531.01 | ||
Enterprise Value to Revenue 400.62 | Enterprise Value to EBITDA -7.35 | Shares Outstanding 42876015 | Shares Floating 37588545 |
Shares Outstanding 42876015 | Shares Floating 37588545 | ||
Percent Insiders 3.36 | Percent Institutions 105.5 |
About Dianthus Therapeutics Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-09-12 | President, CEO & Director Mr. Marino Garcia M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://dianthustx.com |
Full time employees 78 | Website https://dianthustx.com | ||
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.